Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 12/20 | 0.47 |
| ▸ | GSK3B | P49841 | 11/20 | 0.47 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572932 | 0.92 | DYRK1A (0.41) | DYRK1AGSK3BCHRNA3CHRNA7 | |
| SCHEMBL1572444 | 0.89 | RBP4 (0.47) | DYRK1AGSK3BRBP4CHRNA3CHRNA7 | |
| SCHEMBL1573183 | 0.87 | GSK3B (0.53) | DYRK1AGSK3BRBP4 | |
| SCHEMBL1572635 | 0.83 | LRRK2 (0.44) | DYRK1AGSK3BRBP4CLK2CLK3 | |
| SCHEMBL4529923 | 0.82 | CCNC (0.42) | DYRK1ARBP4CHRNA7 | |
| SCHEMBL4232915 | 0.81 | GSK3B (0.46) | GSK3BRBP4CHRNA3CHRNA7 | |
| SCHEMBL3861579 | 0.81 | GSK3B (0.52) | DYRK1AGSK3BRBP4 | |
| SCHEMBL1572456 | 0.80 | RBP4 (0.41) | RBP4CHRNA3CHRNA7 | |
| SCHEMBL1635356 | 0.80 | LRRK2 (0.42) | DYRK1AGSK3BRBP4CLK2CLK3 | |
| SCHEMBL1572778 | 0.80 | CHRNA7 (0.52) | RBP4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745046-B1 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZIOSOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2011-04-13 | — | — | EP | claimed |
| US-7632831-B2 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-15 | — | — | US | claimed |
| EP-1745046-A2 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZIOSOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2007-01-24 | — | — | EP | claimed |
| US-20050272735-A1 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-12-08 | — | — | US | claimed |
| WO-2005111038-A2 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | claimed |
| EP-1745046-B1 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZIOSOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20090325939-A1 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-12-31 | — | — | US | disclosed |
| US-20090325939-A1 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-12-31 | — | — | US | disclosed |
| US-20090325939-A1 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-12-31 | — | — | US | disclosed |
| US-7632831-B2 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632831-B2 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632831-B2 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1745046-A2 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZIOSOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050272735-A1 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-12-08 | — | — | US | disclosed |
| WO-2005111038-A2 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325939-A1 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA1, CHRNA5 | DYRK1A 2107/4885GSK3B 1110/4885RBP4 3840/4885 |
| US-20050272735-A1 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | CHRNA7, CHRNA1, CHRNA5 | DYRK1A 2107/4885GSK3B 1110/4885RBP4 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.